<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793935</url>
  </required_header>
  <id_info>
    <org_study_id>SMRI #: 12T-001</org_study_id>
    <nct_id>NCT01793935</nct_id>
  </id_info>
  <brief_title>Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia</brief_title>
  <official_title>Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K.N. Roy Chengappa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or
      to build resistance to stress or diseases in indigenous medical systems in India for
      centuries. Modern scientific data for WSE indicate several bioactive molecules (withanolides,
      withanosides, indosides, withaferin-A, others) with significant immunomodulatory,
      anti-inflammatory and stress reducing properties.

      This study will examine whether a standardized extract of Withania Somnifera (WSE; Sensoril®)
      will improve total, positive, negative symptoms, and stress in patients with schizophrenia.
      The study will examine whether WSE reduces PANSS positive and negative symptoms and stress
      scores in subjects, and whether these improvements are mediated by changes in inflammatory
      immune indices. An additional aim will determine if patients receiving WSE will have fewer
      adjustments to their psychotropic medications that those assigned to placebo. The study will
      examine whether WSE will re-balance Th1/Th2 ratios (cytokine measures) and mediate a
      reduction of elevated hs-CRP levels. It is hypothesized that those subjects whose Th1/Th2
      ratios normalize will likely have a greater magnitude of clinical improvement versus those
      subjects whose immune ratios remain unbalanced.

      The proposal is a 12-week, double-blind, placebo-controlled RCT of WSE added to antipsychotic
      medications in approximately 60 or more patients with schizophrenia with an exacerbation of
      symptoms. If efficacy is affirmed, this low cost extract could be studied further, and used
      quite readily across low, middle and high income countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to determine whether a standardized extract of Withania somnifera will
      reduce psychopathology scores (PANSS total) and stress scores(PSS total) in persons with
      schizophrenia?

      The study will also determine whether WSE reduces measures of positive and negative and
      general symptoms of schizophrenia (PANSS subscale scores)?

      Another primary aim will be to determine if changes in antipsychotic and/or other
      psychotropic medications (lithium, anticonvulsants, antidepressants, anxiolytic agents or
      hypnotics) (examples: dosage escalation or reductions or switch or stoppage) will favor the
      group receiving the standardized Withania somnifera extract versus those receiving placebo.
      Even though we expect changes in antipsychotic medications to occur when patients experience
      an exacerbation of psychotic symptoms (or other psychiatric symptoms), we hypothesize that
      those receiving the standardized Withania somnifera extract will experience fewer medication
      adjustments then those assigned to placebo.

      A secondary aim is to determine whether WSE will rebalance TH1/TH2 ratios (cytokine measures)
      and mediate a reduction of elevated hs-CRP levels? The study will assess whether those
      subjects whose TH1/TH2 ratios normalize have a greater magnitude of clinical improvement vs.
      those subjects whose immune ratios remain unbalanced. Similarly, the study will assess
      whether reduction of hsCRP levels correlate with improvements in PANSS total and subscale
      scores or the PSS total scores.

      Eighty or more patients with DSM IV TR (or if instituted by the study initiation: DSM V)
      schizophrenia or schizoaffective disorder will be screened and 60 or more eligible patients
      will be enrolled in a 12 week placebo controlled double blind study. Subjects who have
      experienced an exacerbation of positive symptoms (delusions, hallucinations, etc). Subjects
      receiving medications that affect the immune-inflammatory system will be excluded and those
      receiving antibiotics, antiviral or anti-parasitic medications will be excluded.

      Base line laboratory and EKG examination will be carried out to establish eligibility for
      study participation. In addition specific laboratory analyses of immune markers namely
      interleukin-2, interferon gamma, interleukin-4, interleukin 6 and high sensitivity C-Reactive
      Protein will be carried out.

      Sixty or more patients will be randomly assigned to receive either WSE or matching placebo
      starting with 1 capsule of 250 mg strength twice a day (total daily dose = 500 mg) for the
      first week which will be increased to 2 capsules of 250 mg twice daily (total daily dose =
      1000 mg) for a total treatment period of 12 weeks. An assessment of psychopathology (PANSS)
      and stress will be carried out at each scheduled visit. Assessments of safety including vital
      signs and treatment emergent adverse events will also be carried out at each visit.
      Immune-inflammatory markers will be re-assessed at the final visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 7, 2016</completion_date>
  <primary_completion_date type="Actual">July 7, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) measures symptom severity in patients with psychotic illnesses. It yields a total score as well as subscores for Positive symptoms, Negative symptoms and General symptoms.
PANSS Positive subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome.
PANSS Negative subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome.
General Psychopathology subscale consists of 16 items - (minimum score = 16, maximum score = 112) - Higher values represent a worse outcome.
PANSS Total Score - The 3 subscales scores are summed to compute a PANSS Total score. The minimum PANSS total score = 30, maximum = 210 - Higher values represent a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale (PSS)</measure>
    <time_frame>Baseline and 12 weeks or end of treatment</time_frame>
    <description>The Perceived Stress Scale (PSS) was developed to measure the degree to which situations in one's life are appraised as stressful.
Perceived Stress Scale Scoring Each item is rated on a 5-point scale ranging from never (0) to very often (4). Positively worded items are reverse scored, and the ratings are summed, with higher scores indicating more perceived stress.
PSS-10 scores are obtained by reversing the scores on the four positive items:
For example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the positively stated items. Total score can range from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered high stress,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI-S) - Severity</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 0 = not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients - The higher the score the worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Score of 1, 2, or 3 on the Clinical Global Impression Improvement Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: Possible ratings are: 1= Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5= Minimally worse, 6= Much worse, 7=Very much worse.
The higher the score the worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker IL-2</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Changes in immune marker IL-2 will be assessed in response to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker IL-4</measure>
    <time_frame>Baseline and12 weeks or end of study</time_frame>
    <description>Changes in immune marker IL-4 will be assessed in response to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker IL-6</measure>
    <time_frame>Changes from Baseline in Immune markers at 12 weeks or end of study</time_frame>
    <description>Changes in immune marker IL-6 will be assessed in response to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker IFN-Y (Gamma)</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Changes in immune marker IFN-Y (gamma) will be assessed in response to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker Hs-CRP (High Sensitivity C Reactive Protein)</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Changes in immune marker hs-CRP (high sensitivity C Reactive Protein) will be assessed in response to study medication.
hsCRP - mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Marker S-100B</measure>
    <time_frame>Baseline and 12 weeks or end of treatment</time_frame>
    <description>Changes in immune marker S-100B will be assessed in response to study medication.
Elisa
Sensitivity 2.7 picogm/ml
Range 2.7 to 2000 picogm/ml</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vital Signs - Weight</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Clinically significant changes in weight will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs - Body Mass Index</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Clinically significant changes in BMI will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs - Blood Pressure Systolic and Diastolic</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Clinically significant changes in BP will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs - Pulse</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Clinically significant changes in Pulse will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs - Temperature</measure>
    <time_frame>Baseline and 12 weeks or end of study</time_frame>
    <description>Clinically significant changes in Temperature will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory Analytes</measure>
    <time_frame>Change from Baseline in Laboratory Analytes at 12 weeks or end of study</time_frame>
    <description>Changes in laboratory analytes will be classified as &quot;normal&quot; or &quot;abnormal&quot; (example: white blood cell counts)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Sensoril®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sensoril® is a proprietary extract of Withania Somnifera</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sensoril®</intervention_name>
    <description>Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
    <arm_group_label>Sensoril®</arm_group_label>
    <other_name>Ashwagandha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>&quot;Sugar Pill&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males or females (≥ 18 years, to 75 years)

          2. DSM IV TR diagnosis of schizophrenia or schizoaffective disorder (If officially
             instituted by study initiation: DSM V diagnoses will be used).

          3. Ability to provide informed written consent

          4. PANSS total score ≥ 60, positive symptom cluster, (delusions, conceptual
             disorganization, hallucinatory behavior, excitement, grandiosity,
             suspiciousness/persecution, hostility and unusual thought content with at least 2
             items scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 =
             absent to 7 = extreme

          5. Current symptom exacerbation ≥ 2 weeks, but ≤ 1 year

          6. Receiving anti-psychotic medications for ≥ 4 weeks

          7. For women of child bearing age, a negative pregnancy test at screening.

        Exclusion Criteria:

          1. Testing positive for illicit substances (marijuana or alcohol use will be assessed on
             a case by case basis, caffeine and nicotine are excepted)

          2. Receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate,
             others) will be reviewed on a case by case basis

          3. Seriously unstable medical illnesses

          4. Pregnant or breast feeding women

          5. Known allergy or history of serious adverse event with WSE

          6. Subjects who may require imminent hospitalization (examples: suicidal or aggressive
             behavior)

          7. Currently receiving antibiotics, anti-viral, or anti-parasitic medications

          8. Currently receiving immunosuppressive medications (e.g. corticosteroids, chemotherapy
             or transplantation or HIV/AIDs associated drugs).

          9. Currently receiving NSAIDs or Aspirin (&gt;81 mg/day) on a daily basis or PRN use &gt;
             2x/week (in the last 4 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KN Roy Chengappa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute &amp; Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <results_first_submitted>July 7, 2017</results_first_submitted>
  <results_first_submitted_qc>October 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2017</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>K.N. Roy Chengappa</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Sensoril</keyword>
  <keyword>Withania Somnifera extract</keyword>
  <keyword>Total/ Positive / Negative Symptoms</keyword>
  <keyword>Stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Immunomodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sensoril®</title>
          <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient did not take study medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>34 subjects were randomized in each group but 1 subject in each group never came to pick up study medication and therefore are not included in the Overall number of participants analyzed in each outcome measure. They did not contribute any data to the intention to treat group.</population>
      <group_list>
        <group group_id="B1">
          <title>Sensoril®</title>
          <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.18" spread="12.90"/>
                    <measurement group_id="B2" value="47.38" spread="11.37"/>
                    <measurement group_id="B3" value="46.28" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis Schizophrenia or Schizoaffective</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diagnosis Schizophrenia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diagnosis Schizoaffective</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lifetime psychiatric hospitalizations</title>
          <units>psychiatric hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.71" spread="6.45"/>
                    <measurement group_id="B2" value="7.76" spread="6.90"/>
                    <measurement group_id="B3" value="7.74" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at onset of 1st episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.32" spread="10.89"/>
                    <measurement group_id="B2" value="24.00" spread="7.67"/>
                    <measurement group_id="B3" value="24.16" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smokers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive and Negative Syndrome Scale (PANSS)</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) measures symptom severity in patients with psychotic illnesses. It yields a total score as well as subscores for Positive symptoms, Negative symptoms and General symptoms.
PANSS Positive subscale consists of 7 Items - (minimum score = 7, maximum score = 49) – Higher values represent a worse outcome.
PANSS Negative subscale consists of 7 Items - (minimum score = 7, maximum score = 49) – Higher values represent a worse outcome.
General Psychopathology subscale consists of 16 items - (minimum score = 16, maximum score = 112) – Higher values represent a worse outcome.
PANSS Total Score - The 3 subscales scores are summed to compute a PANSS Total score. The minimum PANSS total score = 30, maximum = 210 – Higher values represent a worse outcome</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS)</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) measures symptom severity in patients with psychotic illnesses. It yields a total score as well as subscores for Positive symptoms, Negative symptoms and General symptoms.
PANSS Positive subscale consists of 7 Items - (minimum score = 7, maximum score = 49) – Higher values represent a worse outcome.
PANSS Negative subscale consists of 7 Items - (minimum score = 7, maximum score = 49) – Higher values represent a worse outcome.
General Psychopathology subscale consists of 16 items - (minimum score = 16, maximum score = 112) – Higher values represent a worse outcome.
PANSS Total Score - The 3 subscales scores are summed to compute a PANSS Total score. The minimum PANSS total score = 30, maximum = 210 – Higher values represent a worse outcome</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PANSS Positive Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.58" spread="3.34"/>
                    <measurement group_id="O2" value="19.97" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Positive at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.39" spread="3.94"/>
                    <measurement group_id="O2" value="15.33" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Negative Baselin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.52" spread="4.52"/>
                    <measurement group_id="O2" value="17.27" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Negative at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.97" spread="4.46"/>
                    <measurement group_id="O2" value="15.88" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS General Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.79" spread="5.04"/>
                    <measurement group_id="O2" value="33.24" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS General at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.55" spread="4.99"/>
                    <measurement group_id="O2" value="30.27" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Total at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.88" spread="8.00"/>
                    <measurement group_id="O2" value="69.48" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS total at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.91" spread="11.40"/>
                    <measurement group_id="O2" value="61.48" spread="14.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Stress Scale (PSS)</title>
        <description>The Perceived Stress Scale (PSS) was developed to measure the degree to which situations in one’s life are appraised as stressful.
Perceived Stress Scale Scoring Each item is rated on a 5-point scale ranging from never (0) to very often (4). Positively worded items are reverse scored, and the ratings are summed, with higher scores indicating more perceived stress.
PSS-10 scores are obtained by reversing the scores on the four positive items:
For example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the positively stated items. Total score can range from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered high stress,</description>
        <time_frame>Baseline and 12 weeks or end of treatment</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Stress Scale (PSS)</title>
          <description>The Perceived Stress Scale (PSS) was developed to measure the degree to which situations in one’s life are appraised as stressful.
Perceived Stress Scale Scoring Each item is rated on a 5-point scale ranging from never (0) to very often (4). Positively worded items are reverse scored, and the ratings are summed, with higher scores indicating more perceived stress.
PSS-10 scores are obtained by reversing the scores on the four positive items:
For example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the positively stated items. Total score can range from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered high stress,</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSS score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.48" spread="7.27"/>
                    <measurement group_id="O2" value="20.55" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSS score at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" spread="5.87"/>
                    <measurement group_id="O2" value="18.09" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale (CGI-S) - Severity</title>
        <description>The Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 0 = not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients – The higher the score the worse outcome</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale (CGI-S) - Severity</title>
          <description>The Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 0 = not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients – The higher the score the worse outcome</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CGI Severity score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="0.24"/>
                    <measurement group_id="O2" value="4.09" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGI Severity score at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.49"/>
                    <measurement group_id="O2" value="3.97" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Score of 1, 2, or 3 on the Clinical Global Impression Improvement Scale</title>
        <description>The Clinical Global Impression – Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: Possible ratings are: 1= Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5= Minimally worse, 6= Much worse, 7=Very much worse.
The higher the score the worse outcome</description>
        <time_frame>12 weeks</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Score of 1, 2, or 3 on the Clinical Global Impression Improvement Scale</title>
          <description>The Clinical Global Impression – Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: Possible ratings are: 1= Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5= Minimally worse, 6= Much worse, 7=Very much worse.
The higher the score the worse outcome</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker IL-2</title>
        <description>Changes in immune marker IL-2 will be assessed in response to study medication.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>IL-2 levels undetectable.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker IL-2</title>
          <description>Changes in immune marker IL-2 will be assessed in response to study medication.</description>
          <population>IL-2 levels undetectable.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">data cannot be summarized- IL-2 levels undetectable</measurement>
                    <measurement group_id="O2" value="NA">data cannot be summarized- IL-2 levels undetectable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker IL-4</title>
        <description>Changes in immune marker IL-4 will be assessed in response to study medication.</description>
        <time_frame>Baseline and12 weeks or end of study</time_frame>
        <population>Data cannot be summarized- IL-4 levels undetectable</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker IL-4</title>
          <description>Changes in immune marker IL-4 will be assessed in response to study medication.</description>
          <population>Data cannot be summarized- IL-4 levels undetectable</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">data cannot be summarized- IL-4 levels undetectable</measurement>
                    <measurement group_id="O2" value="NA">data cannot be summarized- IL-4 levels undetectable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker IL-6</title>
        <description>Changes in immune marker IL-6 will be assessed in response to study medication.</description>
        <time_frame>Changes from Baseline in Immune markers at 12 weeks or end of study</time_frame>
        <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for IL-6.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker IL-6</title>
          <description>Changes in immune marker IL-6 will be assessed in response to study medication.</description>
          <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for IL-6.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL6 level at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="2.53"/>
                    <measurement group_id="O2" value="4.29" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL 6 level at end of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="2.51"/>
                    <measurement group_id="O2" value="3.87" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker IFN-Y (Gamma)</title>
        <description>Changes in immune marker IFN-Y (gamma) will be assessed in response to study medication.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>data cannot be summarized IFN-Y (gamma) levels undetectable</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker IFN-Y (Gamma)</title>
          <description>Changes in immune marker IFN-Y (gamma) will be assessed in response to study medication.</description>
          <population>data cannot be summarized IFN-Y (gamma) levels undetectable</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">data cannot be summarized IFN-Y (gamma) levels undetectable</measurement>
                    <measurement group_id="O2" value="NA">data cannot be summarized IFN-Y (gamma) levels undetectable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker Hs-CRP (High Sensitivity C Reactive Protein)</title>
        <description>Changes in immune marker hs-CRP (high sensitivity C Reactive Protein) will be assessed in response to study medication.
hsCRP - mg/L</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for hs-CRP.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker Hs-CRP (High Sensitivity C Reactive Protein)</title>
          <description>Changes in immune marker hs-CRP (high sensitivity C Reactive Protein) will be assessed in response to study medication.
hsCRP - mg/L</description>
          <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for hs-CRP.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Rx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="8.57"/>
                    <measurement group_id="O2" value="6.27" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Rx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="5.09"/>
                    <measurement group_id="O2" value="7.82" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Marker S-100B</title>
        <description>Changes in immune marker S-100B will be assessed in response to study medication.
Elisa
Sensitivity 2.7 picogm/ml
Range 2.7 to 2000 picogm/ml</description>
        <time_frame>Baseline and 12 weeks or end of treatment</time_frame>
        <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for S-100B.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Marker S-100B</title>
          <description>Changes in immune marker S-100B will be assessed in response to study medication.
Elisa
Sensitivity 2.7 picogm/ml
Range 2.7 to 2000 picogm/ml</description>
          <population>The &quot;number analyzed&quot; differs from the &quot;overall number of participants analyzed&quot; because not all participants had baseline and end of treatment values for S-100B.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S100B pre Rx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.36" spread="89.92"/>
                    <measurement group_id="O2" value="34.95" spread="56.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100B end of Rx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.38" spread="79.44"/>
                    <measurement group_id="O2" value="62.49" spread="173.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs - Weight</title>
        <description>Clinically significant changes in weight will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Weight</title>
          <description>Clinically significant changes in weight will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body Weight at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.61" spread="49.57"/>
                    <measurement group_id="O2" value="191.33" spread="41.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Weight at end of Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.00" spread="51.94"/>
                    <measurement group_id="O2" value="193.06" spread="41.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs - Body Mass Index</title>
        <description>Clinically significant changes in BMI will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Body Mass Index</title>
          <description>Clinically significant changes in BMI will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BMI at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" spread="7.56"/>
                    <measurement group_id="O2" value="30.36" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI at end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.33" spread="8.04"/>
                    <measurement group_id="O2" value="30.56" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs - Blood Pressure Systolic and Diastolic</title>
        <description>Clinically significant changes in BP will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Blood Pressure Systolic and Diastolic</title>
          <description>Clinically significant changes in BP will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.67" spread="10.53"/>
                    <measurement group_id="O2" value="123.42" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP at end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.36" spread="9.30"/>
                    <measurement group_id="O2" value="118.39" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.15" spread="7.95"/>
                    <measurement group_id="O2" value="76.52" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP at end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.06" spread="7.31"/>
                    <measurement group_id="O2" value="75.55" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs - Pulse</title>
        <description>Clinically significant changes in Pulse will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Pulse</title>
          <description>Clinically significant changes in Pulse will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.18" spread="13.38"/>
                    <measurement group_id="O2" value="74.91" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse at end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.42" spread="14.64"/>
                    <measurement group_id="O2" value="76.42" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs - Temperature</title>
        <description>Clinically significant changes in Temperature will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
        <time_frame>Baseline and 12 weeks or end of study</time_frame>
        <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Sensoril®</title>
            <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Temperature</title>
          <description>Clinically significant changes in Temperature will be assessed for &quot;normal&quot; or &quot;abnormal&quot; following randomization to 12 weeks or end of study.</description>
          <population>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</population>
          <units>degrees F</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.38" spread="0.57"/>
                    <measurement group_id="O2" value="97.36" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature at end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.37" spread="0.73"/>
                    <measurement group_id="O2" value="97.31" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Laboratory Analytes</title>
        <description>Changes in laboratory analytes will be classified as &quot;normal&quot; or &quot;abnormal&quot; (example: white blood cell counts)</description>
        <time_frame>Change from Baseline in Laboratory Analytes at 12 weeks or end of study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were evaluated during the study period (12 weeks)</time_frame>
      <desc>34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes</desc>
      <group_list>
        <group group_id="E1">
          <title>Sensoril®</title>
          <description>Sensoril® is a proprietary extract of Withania Somnifera
Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>loose stools/diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dyspepsia (heartburn)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue/lathargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>hyperactive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>worsening of psychiatric symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. K.N. Roy Chengappa - PI</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-5006</phone>
      <email>chengappakn@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

